KRAS and familial pancreatic carcinoma: Specifically, mutant KRAS pancreatic cancer cells contain a CD133+/Mitohigh subpopulation of cells resistant to KRAS ablation that also exhibit enhanced mitochondrial metabolism and augmented OXPHOS dependency [55].